Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 1332Carcinoma, Non-Small-Cell Lung 631Breast Neoplasms 162Neoplasms 99Small Cell Lung Carcinoma 93Prostatic Neoplasms 86Colorectal Neoplasms 79Motor Activity 63Colonic Neoplasms 62Head and Neck Neoplasms 60Esophageal Neoplasms 49Disease 46Pancreatic Neoplasms 45Melanoma 41Stomach Neoplasms 39Urinary Bladder Neoplasms 37Ovarian Neoplasms 37Pleural Effusion, Malignant 36Neoplasm Metastasis 35Brain Neoplasms 29Gastrointestinal Neoplasms 28Pulmonary Disease, Chronic Obstructive 27Anxiety Disorders 27Lung Diseases 26Liver Neoplasms 26Carcinoma, Renal Cell 26Adenocarcinoma of Lung 26Thoracic Neoplasms 25Mesothelioma 24Lymphoma 24

Interventions

Radiotherapy 2Immune Checkpoint Inhibitors 2aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Advanced NSCLC × Thoracic × Clear all
NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated
116 enrolled
Thoracic

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡